Wuxi Fuqi Pharmaceutical

Wuxi Fuqi Pharmaceutical, also known as Wuxi Fortune Pharmaceutical, is a leading Chinese manufacturer of fermentation-based active pharmaceutical ingredients (APIs), particularly glycopeptide antibiotics. Founded in 1992 and headquartered in Wuxi, China, the company was acquired by China Grand Pharmaceutical and Healthcare Holdings in 2015. It is globally recognized for its production of Vancomycin Hydrochloride and Teicoplanin, maintaining high-quality standards with certifications from the US FDA and EU GMP. The company's product portfolio also includes aminoglycosides such as Tobramycin and Netilmicin. Wuxi Fuqi serves as a critical supplier to the international pharmaceutical market, leveraging its expertise in large-scale fermentation and purification.